

CITATION REPORT

List of articles citing

Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD

DOI: 10.1056/nejmoa1916046

New England Journal of Medicine, 2020, 383, 35-48.

Source: <https://exaly.com/paper-pdf/76800673/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
231	Triple Inhaled Therapy in COPD. <i>New England Journal of Medicine</i> , 2020 , 383, 1393	59.2	1
230	Formoterol for the Treatment of Chronic Obstructive Pulmonary Disease. 2020 , 15, 3105-3122		0
229	Time for a change: anticipating the diagnosis and treatment of COPD. 2020 , 56,		10
228	Dual Bronchodilator in the Era of Triple Therapy. 2020 , 15, 2695-2705		5
227	Optimizing de-escalation of inhaled corticosteroids in COPD: a systematic review of real-world findings. 2020 , 13, 977-990		5
226	Current Status of the Treatment of COPD in China: A Multicenter Prospective Observational Study. 2020 , 15, 3227-3237		7
225	Prescribing Pathways to Triple Therapy: A Retrospective Observational Study of Adults with Chronic Obstructive Pulmonary Disease in the UK. 2020 , 15, 3261-3271		3
224	Real-Life Clinical and Functional Effects of Fluticasone Furoate/Umeclidinium/Vilanterol-Combined Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease. 2021 , 100, 127-134		6
223	The role of triple therapy in the management of COPD. 2020 , 13, 865-874		4
222	Glycopyrrolate and formoterol fumarate for the treatment of COPD. 2021 , 15, 13-25		1
221	Pharmacotherapy and Lung Function Decline in Patients with Chronic Obstructive Pulmonary Disease. A Systematic Review. 2021 , 203, 689-698		10
220	Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT Trial. 2021 , 7, 101-118		2
219	Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study. 2021 , 203, 553-564		38
218	A Patient Charter for Chronic Obstructive Pulmonary Disease. 2021 , 38, 11-23		5
217	Reigniting the TORCH: Chronic Obstructive Pulmonary Disease Mortality and Inhaled Corticosteroids Revisited. 2021 , 203, 531-532		3
216	Rate of Decline of FEV as a Biomarker of Survival?. 2021 , 203, 663-665		2
215	Efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review. 2021 , 22, 611-620		4

214	Evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies. 2021 , 15, 143-152	15
213	The triple therapy for chronic obstructive pulmonary disease increases the risk of pneumonias compared to the dual-bronchodilator therapy. 2021 , 13, 6099-6101	
212	Self-reported COPD Medication Use and Adherence in the COPD Foundation Patient- Powered Registry Network. 2021 , 8, 474-487	0
211	Drug Delivery in Respiratory Diseases: Current Opportunities, Molecular and Cellular Mechanism, and Future Challenges. 2021 , 847-902	
210	Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Exacerbation Outcomes in Patients with COPD without a Recent Exacerbation History: A Subgroup Analysis of KRONOS. 2021 , 16, 179-189	7
209	Triple Therapy Is Also Effective in Real-World When Used in Chronic Obstructive Pulmonary Disease Patients Who Are Frequent Exacerbators. 2021 , 100, 93-95	1
208	Triple therapy in chronic obstructive pulmonary disease: consideration under new evidence. 2021 , 134, 1513	
207	Inhaled long-acting muscarinic antagonists in asthma - A narrative review. 2021 , 85, 14-22	8
206	Letter to editor - a response to: Efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review. 2021 , 22, 939-941	1
205	Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPD. 2021 , 16, 499-517	4
204	[Inhaled therapies in COPD - all patients on fixed triple?]. 2021 , 146, 471-473	
203	Effectiveness and Safety of COPD Maintenance Therapy with Tiotropium/Olodaterol versus LABA/ICS in a US Claims Database. 2021 , 38, 2249-2270	1
202	Contemporary Concise Review 2020: Chronic obstructive pulmonary disease. 2021 , 26, 493-500	
201	Spanish COPD Guidelines (GesEPOC) 2021: Updated Pharmacological treatment of stable COPD. 2021 , 58, 69-69	22
200	Chronic obstructive pulmonary disease. 2021 , 5, 84-88	
199	Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial. 2021 , 22, 90	2
198	ETHOS trial: Discussions from @respandsleepjc (#rsjc) Journal Club. 2021 , 5, 199-201	
197	Triple-Therapy Trials for Chronic Obstructive Pulmonary Disease: Methodological Considerations in the Mortality Effect. 2021 , 203, 925-926	

196	[Chronic obstructive pulmonary disease: the right treatment for the right patient]. 2021 , 62, 679-685	0
195	Mortality in ETHOS: A Question of "Power". 2021 , 203, 926-927	2
194	Treatment of COPD Groups GOLD A and B with Inhaled Corticosteroids in the COSYCONET Cohort - Determinants and Consequences. 2021 , 16, 987-998	2
193	Reply to Lpez-Campos and to Rogliani and Calzetta. 2021 , 203, 927-928	
192	Dual bronchodilator versus inhaled corticosteroid/long-acting β agonist in patients with chronic obstructive pulmonary disease: A meta-analysis of randomized controlled trials. 2021 , 93, 107447	2
191	Adherence to Treatment Recommendations for Chronic Obstructive Pulmonary Disease - Results from the Swedish National Airway Register. 2021 , 16, 909-918	6
190	Chronic obstructive pulmonary disease exacerbation fundamentals: Diagnosis, treatment, prevention and disease impact. 2021 , 26, 532-551	11
189	Single inhaler triple therapy in COPD - all that glitters is not gold. 2021 , 91,	
188	Pharmacological treatment of stable chronic obstructive pulmonary disease. 2021 , 26, 643-651	5
187	Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol Fumarate versus Other Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis. 2021 , 38, 3089-3112	3
186	Spanish COPD guidelines (GesEPOC) 2021: Updated pharmacological treatment of stable COPD. 2021 , 58, T69-T69	9
185	Reply to: "Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies" [Letter]. 2021 , 16, 1299-1301	
184	Comparison of Immediate and Sequential Withdrawal of a Systemic Glucocorticoid in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Multicenter, Randomized, Double-Blind, Parallel-Controlled, Open-Label Study. 2021 , 8, 639079	
183	Correlation of Luminal Mucus Score in Large Airways with Lung Function and Quality of Life in Severe Acute Exacerbation of COPD: A Cross-Sectional Study. 2021 , 16, 1449-1459	2
182	Signal ffrReduktion der Mortalitfr durch inhalative Triple-Therapie bei schwerer COPD. 2021 , 13, 24-25	
181	Response to the Letter to the Editor Regarding "Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies" [Response to Letter]. 2021 , 16, 1227-1229	
180	Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial. 2021 , 7,	0
179	Inhaled Corticosteroids and the Pneumonia Risk in Patients With Chronic Obstructive Pulmonary Disease: A Meta-analysis of Randomized Controlled Trials. 2021 , 12, 691621	3

178	Update on Asthma-COPD Overlap (ACO): A Narrative Review. 2021 , 16, 1783-1799	10
177	Triple versus LAMA/LABA combination therapy for patients with COPD: a systematic review and meta-analysis. 2021 , 22, 183	3
176	Triple versus LAMA/LABA combination therapy for Japanese patients with COPD: A systematic review and meta-analysis. 2021 , 60, 90-90	0
175	Adrenergic and Glucocorticoid Receptors in the Pulmonary Health Effects of Air Pollution. 2021 , 9,	2
174	Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD. 2021 , 30,	8
173	Medium-dose ICS-containing FDCs reduce all-cause mortality in COPD patients: an in-depth analysis of dual and triple therapies. 2021 , 1-9	0
172	Functional respiratory imaging assessment of budesonide/glycopyrrolate/formoterol fumarate and glycopyrrolate/formoterol fumarate metered dose inhalers in patients with COPD: the value of inhaled corticosteroids. 2021 , 22, 191	1
171	Single-inhaler triple vs single-inhaler dual therapy in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized control trials. 2021 , 22, 209	3
170	Budesonide/Glycopyrrolate/Formoterol Fumarate Co-suspension Metered Dose Inhaler: A Triple Therapy for the Treatment of Chronic Obstructive Pulmonary Disease. 2021 , 10600280211038353	
169	A randomized controlled trial of glycopyrrolate administered by metered dose inhaler in patients with uncontrolled asthma despite ICS/LABA treatment. 2021 , 1-13	1
168	COPD maintenance medication is linked to left atrial size: Results from the COSYCONET cohort. 2021 , 185, 106461	3
167	Benefits of budesonide/glycopyrrolate/formoterol fumarate (BGF) on symptoms and quality of life in patients with COPD in the ETHOS trial. 2021 , 185, 106509	5
166	Budesonide/Glycopyrronium/Formoterol: A Review in COPD. 2021 , 81, 1411-1422	3
165	CONQUEST Quality Standards: For the Collaboration on Quality Improvement Initiative for Achieving Excellence in Standards of COPD Care. 2021 , 16, 2301-2322	2
164	COPD, Pulmonary Fibrosis and ILAs in Aging Smokers: The Paradox of Striking Different Responses to the Major Risk Factors. 2021 , 22,	1
163	Comparative efficacy of single-inhaler triple therapies for COPD: A protocol for systematic review and network meta-analysis. 2021 , 16, e0255545	
162	Inhaled Corticosteroids and the Lung Microbiome in COPD. 2021 , 9,	2
161	Single inhaler triple therapy (SITT) in asthma: Systematic review and practice implications. 2021 ,	3

160	Triple Therapy in COPD: Time for Adaptive Selection Trials. 2021 , 1-5	1
159	Asthma COPD overlap: Insights into cellular and molecular mechanisms. 2021 , 101021	1
158	Real-World Effectiveness of Inhalation Therapy Among Patients With Symptomatic COPD in China: A Multicenter Prospective Study. 2021 , 12, 753653	4
157	Evaluation of small airway function and its application in patients with chronic obstructive pulmonary disease (Review). 2021 , 22, 1386	0
156	Ten Commandments for Randomized Trials of Pharmacological Therapy for COPD and Other Lung Diseases. 2021 , 18, 485-492	
155	Normal limits for oscillometric bronchodilator responses and relationships with clinical factors. 2021 , 7,	2
154	Inhaled corticosteroids in COPD: risk and benefits. 2021 ,	0
153	Update on guidelines for the treatment of COPD in Taiwan using evidence and GRADE system-based recommendations. 2021 , 120, 1821-1844	1
152	Personalising add-on treatment with inhaled corticosteroids in patients with chronic obstructive pulmonary disease: a benefit-harm modelling study. 2021 , 3, e644-e653	0
151	Overview of Current Management of COPD. 2022 , 631-641	0
150	Chronic obstructive pulmonary disease: moving from symptom relief to mortality reduction. 2021 , 14, 20406223211014028	1
149	Journal Club: Do Inhaled Corticosteroids Reduce All-Cause Mortality in Chronic Obstructive Pulmonary Disease? What is the Latest Evidence?. 2021 , 8, 1-3	
148	Improvements in lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler dual therapies in patients with COPD: a sub-study of the ETHOS trial. 2021 , 15, 17534666211034329	
147	Inhalation delivery dramatically improves the efficacy of topotecan for the treatment of local and distant lung cancer. 2021 , 28, 767-775	5
146	Reply to Han et al.: impact on mortality of triple ICS/LABA/LAMA therapy in a population of COPD patients including also subjects with asthma-like profile. 2021 , 15, 579-581	4
145	Inhaled therapy reduces COPD mortality. 2020 , 6,	7
144	Underdiagnosis of obstructive lung disease: findings from the French CONSTANCES cohort. 2021 , 21, 319	0
143	Treatment Trials in Young Patients with COPD and Pre-COPD Patients: Time to Move Forward. 2021 ,	7

142	Narrative Literature Review Guided Approach of Inhaled Corticosteroid de-escalation in Chronic Obstructive Pulmonary Disease. 2021 , 8971900211053771	
141	The Role of Blood Eosinophils in the Management of COPD: An Attempt to Answer the Important Clinical Questions. 2021 , 1-10	
140	Benefit/risk ratio profile of single inhaler triple therapy for bronchial obstructive pulmonary disease patients. 2021 , 31, 645-652	
139	Serum cadmium positively correlates with inflammatory cytokines in patients with chronic obstructive pulmonary disease. 2022 , 37, 151-160	3
138	Eosinophilic endotype of chronic obstructive pulmonary disease: similarities and differences from asthma. 2021 , 36, 1305-1319	1
137	A scintigraphy study of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in patients with moderate-to-very severe chronic obstructive pulmonary disease. 2021 , 22, 261	1
136	A rapidly changing understanding of COPD: World COPD Day from the COPD Foundation. 2021 , 321, L983-L987	1
135	[Asthma-COPD-Overlap - diagnostic and therapeutic management]. 2021 , 146, 1405-1409	
134	COPD mortality and exacerbations in the placebo group of clinical trials over two decades: a systematic review and meta-regression.. 2022 , 8,	0
133	Continuity of Care Assessment Within a Vertically Integrated Care Management Organization Before and After COPD-Related Exacerbations. 2021 , 16, 2755-2767	0
132	Precision medicine in chronic obstructive pulmonary disease: how far have we come?. 2021 ,	0
131	Quantifying the Economic Impact of Delayed Multiple-Inhaler Triple Therapy Initiation in Patients with COPD: A Retrospective Cohort Study of Linked Electronic Medical Record and Hospital Administrative Data in England. 2021 , 16, 2795-2808	
130	Unmet need in the management of chronic obstructive pulmonary disease in the Middle East and Africa region: An expert panel consensus. 2021 , 189, 106641	2
129	Individual trajectory-based care for COPD: getting closer, but not there yet.. 2021 , 7,	0
128	A Non-Interventional, Cross-Sectional Study to Evaluate Factors Relating to Daily Step Counts and Physical Activity in Japanese Patients with Chronic Obstructive Pulmonary Disease: STEP COPD. 2020 , 15, 3385-3396	2
127	Reply to: Reevaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies. 2021 , 15, 577-578	2
126	Pharmacotherapy of chronic obstructive pulmonary disease: Therapeutic considerations with a focus on inhaled corticosteroids. 2020 , 62, e1-e6	
125	Triple Combination Inhalers in Chronic Obstructive Pulmonary Disease and Asthma. 2020 , 5, 18	2

- 124 COPD-Tripeltherapie: Wieviel Steroid muss sein?. **2020**, 74, 716-716
- 123 Triexo Aerosphere: a triple-combination inhaler for COPD. **2021**, 32, 38-39
- 122 Discordant diagnostic criteria for pneumonia in COPD trials: a review. **2021**, 30, 0
- 121 Evaluating a Cox marginal structural model to assess the comparative effectiveness of inhaled corticosteroids versus no inhaled corticosteroid treatment in chronic obstructive pulmonary disease. **2021**, 67, 19-19 0
- 120 Blood eosinophils in COPD: friend or foe?. **2021**, 1-7 0
- 119 A Randomized Controlled Study on the Prevention and Treatment of Chronic Obstructive Pulmonary Disease by Taking Zhenwu Decoction in Sanfutian. **2021**, 11, 157-163
- 118 The role of airway remodeling in the pathogenesis and treatment of chronic obstructive pulmonary disease. **2021**, 8, 96-102
- 117 Beyond Dual Bronchodilation - Triple Therapy, When and Why.. **2022**, 17, 165-180 2
- 116 Evaluating the Impact of Triple Therapy on Mortality in Copd: The End is the Beginning?. **2022**, 1-4
- 115 COPD. **2022**, 199-214
- 114 The Impact of 52-Week Single Inhaler Device Triple Therapy versus Dual Therapy on the Mortality of COPD Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. **2022**, 12, 0
- 113 [Translated article] Spanish COPD guidelines (GesEPOC) 2021: Updated pharmacological treatment of stable COPD.. **2022**, 58, T69-T81 11
- 112 Entwicklung und Fortschritt bei obstruktiven Lungenerkrankungen. **2022**, 19, 74
- 111 Is it Time to Readjust the Doses of Inhaled Corticosteroids in COPD?. **2022**, 0
- 110 Use of single-inhaler triple therapy in the management of obstructive airway disease: Indian medical expertsPreview.. **2022**, 8,
- 109 Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone.. **2022**, 17, 355-370 0
- 108 A Pooled Analysis of Mortality in Patients with COPD Receiving Dual Bronchodilation with and without Additional Inhaled Corticosteroid.. **2022**, 17, 545-558 3
- 107 Triple Therapy in COPD: Can We Welcome the Reduction in Cardiovascular Risk and Mortality?. **2022**, 9, 816843 1

106	New insights into the optimal management of COPD: Extracts from CHEST 2021 annual meeting (October 17-20, 2021).. 2022,	
105	The efficacy and safety of antibiotics and glucocorticoids in the treatment of elderly patients with chronic obstructive emphysema: systematic review and meta-analysis.. 2022, 10, 287	
104	Blood eosinophils to guide inhaled maintenance therapy in a primary care COPD population.. 2022, 8,	0
103	COPD - do the right thing.. 2021, 22, 244	5
102	Impact of Positive Airway Pressure Therapy Adherence on Outcomes in Patients with OSA and COPD.. 2022,	0
101	Impact of COPD Treatment on Survival in Patients with Advanced Non-Small Cell Lung Cancer.. 2022, 11,	
100	A systematic review of blood eosinophils and continued treatment with inhaled corticosteroids in patients with COPD. 2022, 106880	0
99	[Take-home messages from the COPD 2021 biennial of the French Society of Respiratory Diseases. Understanding to so as to better innovate].. 2022,	0
98	Efficacy and Safety of Single Inhaler Triple Therapy Versus Separate Triple Therapy in Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysis.. 2022,	
97	Chronic obstructive pulmonary disease.. 2022,	5
96	Efficacy of ICS versus Non-ICS Combination Therapy in COPD: A Meta-Analysis of Randomised Controlled Trials.. 2022, 17, 1051-1067	0
95	Relationship between prior inhaled corticosteroid use and benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate on exacerbations, symptoms, health-related quality of life, and lung function in patients with chronic obstructive pulmonary disease: Analyses from the ETHOS study.. 2022, 107, 101057	0
94	[Usefulness of closed triple therapy for COPD in primary care].. 2022,	
93	Effectiveness of treatment with dual bronchodilation (LABA/LAMA) compared with combination therapy (LABA/ICS) for patients with COPD: A population-based study. 2022,	1
92	Advances in inhaled corticosteroids for the treatment of chronic obstructive pulmonary disease: what is their value today?. 2022,	0
91	Best Practice Management of Patients With Chronic Obstructive Pulmonary Disease: A Case-Based Review. 2022,	
90	Lack of Association between Inhaled Corticosteroid Use and the Risk of Future Exacerbation in Patients with GOLD Group A Chronic Obstructive Pulmonary Disease. 2022, 12, 916	
89	Relationship between risk, cumulative burden of exacerbations and mortality in patients with COPD: modelling analysis using data from the ETHOS study. 2022, 22,	1

88	Blood Eosinophils and Chronic Obstructive Pulmonary Disease: A GOLD Science Committee 2022 Review.	7
87	Predictive modeling of COPD exacerbation rates using baseline risk factors. 2022 , 16, 175346662211073	0
86	Real-World Status of Medical Care and Treatment of Chronic Obstructive Pulmonary Disease by Respiratory Specialists in Japan.	0
85	Cardiovascular disease in chronic obstructive pulmonary disease: a narrative review. <i>thoraxjnl-2021-218333</i>	1
84	Chronic obstructive pulmonary disease (COPD) mortality trends worldwide: An update to 2019.	1
83	Clinical characteristics, treatment persistence and outcomes among patients with COPD treated with single- or multiple-inhaler triple therapy: a retrospective analysis in Spain. 2022 ,	0
82	Precision medicine in chronic obstructive pulmonary disease. Publish Ahead of Print,	0
81	Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis.	0
80	Clinical and Statistical Perspectives on the ICH E9(R1) Estimand Framework Implementation. 1-6	1
79	Discovery of Clinical Candidate CHF-6366: A Novel Super-soft Dual Pharmacology Muscarinic Antagonist and β Agonist (MABA) for the Inhaled Treatment of Respiratory Diseases. 2022 , 65, 10233-10250	0
78	Association of Inhaled Corticosteroids With All-cause Death Risk in COPD Patients: A Meta-analysis of Sixty Randomized Controlled Trials. 2022 ,	0
77	Pharmacotherapy and Mortality in COPD.	1
76	Definition and Nomenclature of Chronic Obstructive Pulmonary Disease: Time for its Revision.	6
75	Lack of COPD-Related Follow-Up Visits and Pharmacological Treatment in Swedish Primary and Secondary Care. Volume 17, 1769-1780	0
74	Combination Therapy for COPD: Efficacy and Prospects of Multiple Therapy. 8, 64-68	
73	The CO-MIND Study: Chronic Obstructive Pulmonary Disease Management in Daily Practice and Its Implications for Improved Outcomes According to GOLD 2019 Perspective. Volume 17, 1883-1895	
72	Comparing the Efficacy and Safety Profile of Triple Fixed-Dose Combinations in COPD: A Meta-Analysis and IBiS Score. 2022 , 11, 4491	0
71	Cost-effectiveness of integrated disease management for high risk, exacerbation prone, patients with chronic obstructive pulmonary disease in a primary care setting. 2022 , 20,	

- 70 Effect of timing of bronchodilator therapy initiation on exacerbations in patients with chronic obstructive pulmonary disease: a retrospective cohort study. **2022**, 23, ○
- 69 Effect of Recent Exacerbation History on the Efficacy of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease in the FULFIL Trial. Volume 17, 2043-2052 ○
- 68 Effectiveness of pulmonary rehabilitation in individuals with Chronic Obstructive Pulmonary Disease according to inhaled therapy: The Maugeri study. **2022**, 202, 106967 ○
- 67 Single-Inhaler Triple versus Dual Bronchodilator Therapy in COPD: Real-World Comparative Effectiveness and Safety. Volume 17, 1975-1986 ○
- 66 Different inhaled corticosteroid doses in triple therapy for chronic obstructive pulmonary disease: systematic review and Bayesian network meta-analysis. **2022**, 12, ○
- 65 New Perspectives on Chronic Obstructive Pulmonary Disease. Volume 17, 2127-2136 ○
- 64 Validation of Simple Prediction Equations for Step Count in Japanese Patients with Chronic Obstructive Pulmonary Disease. **2022**, 11, 5535 ○
- 63 Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission. **2022**, 400, 921-972 11
- 62 Patients with Chronic Obstructive Pulmonary Disease and Evidence of Eosinophilic Inflammation Experience Exacerbations Despite Receiving Maximal Inhaled Maintenance Therapy. Volume 17, 2187-2200 ○
- 61 Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. 2200302 ○
- 60 Trajectories of Severe Exacerbations of Chronic Obstructive Pulmonary Disease and Their Relationship with Mortality Risk. **2022**, 200, 601-607 ○
- 59 BPCO et Eosinophiles. **2022**, 39, 685-697 ○
- 58 Highlights del 55º Congreso SEPAR. **2022**, 100216 ○
- 57 May a different kinetic mode explain the high efficacy/safety profile of inhaled budesonide?. **2022**, 77, 102167 ○
- 56 Glucocorticoid therapy in respiratory illness: bench to bedside. jim-2021-002161 ○
- 55 Optimal Management of Heart Failure and Chronic Obstructive Pulmonary Disease: Clinical Challenges. Volume 15, 7961-7975 ○
- 54 Integration of the patient-centered medical home to deliver a care bundle for chronic obstructive pulmonary disease management. **2022**, ○
- 53 Managing acute exacerbation of chronic obstructive pulmonary disease: What's new?. **2022**, 11, 287 ○

52	LABA/LAMA as First-Line Therapy for COPD: A Summary of the Evidence and Guideline Recommendations. 2022 , 11, 6623	1
51	Cost-Effectiveness Analysis of Triple Therapy with Budesonide/ Glycopyrronium/ Formoterol Fumarate versus Dual Therapy in Patients with Chronic Obstructive Pulmonary Disease in Spain. Volume 17, 2905-2917	0
50	Clinical implications of low absolute blood eosinophil count in the SPIROMICS COPD cohort. 2022 ,	0
49	Cost-Effectiveness of Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: United Kingdom Analysis Using the ETHOS Study. Volume 17, 2987-3000	0
48	Chronic Obstructive Pulmonary Disease and pneumonia hospitalisation: Association with dose of inhaled corticosteroids. A nationwide cohort study of 52,100 outpatients. 2022 ,	0
47	Prompt initiation of triple therapy following hospitalization for a chronic obstructive pulmonary disease exacerbation in the United States: An analysis of the PRIMUS study. 2022 , 28, 1366-1377	0
46	Response. 2022 , 162, e334-e341	0
45	Cardiovascular predictors of mortality and exacerbations in patients with COPD. 2022 , 12,	0
44	Letter to the editor in response to the article Yang M, Li Y, Jiang Y, Guo S, He JQ, Sin DD. Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. <i>Eur Respir J.</i> 2022 Sep 22:2200302. 2202208	0
43	COPD: Providing the right treatment for the right patient at the right time. 2022 , 107041	0
42	Which Endoscopic Procedure to Use and in What Patient? Valves, Coils, Foam, and Heat in COPD and Asthma.	0
41	Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges: A Post-Hoc Analysis of Data from ETHOS. Volume 17, 3061-3073	0
40	Effectiveness of triple inhaled therapy in COPD patients: a retrospective analysis of chest tomography and correlation with clinical outcomes. 2022 , 61,	0
39	Was haben wir aus der deutschen COPD-Kohorte COSYCONET gelernt und wie geht es weiter?.	0
38	Actualité concernant la prise en charge médicamenteuse de la BPCO. 2022 , 14, 2S398-2S403	0
37	Inhaled Corticosteroids and COPD. 2023 , 163, 8-9	0
36	Real-World Evidence on the Diagnostic and Clinical Characteristics of Asthma in Japanese Patients with COPD: The ACO Japan Cohort Study. Volume 18, 37-46	0
35	An Effective Random Generalised Linear Model to Predict COPD. 2022 ,	0

- 34 COPD Exacerbation Syndrome: The Spanish Perspective on an Old Dilemma. Volume 17, 3139-3149 ○
- 33 PROMETHEUS: Long-Term Exacerbation and Mortality Benefits of Implementing Single-Inhaler Triple Therapy in the US COPD Population. **2023**, 10, ○
- 32 Toward a Predict and Prevent Approach in Obstructive Airway Diseases. **2023**, ○
- 31 PROMETHEUS: Long-Term Exacerbation and Mortality Benefits of Implementing Single-Inhaler Triple Therapy in the US COPD Population. ○
- 30 Practical Recommendations for a Selection of Inhaled Corticosteroids in COPD: A Composite ICO Chart. **2023**, 13, 213 ○
- 29 Triple therapy in COPD: understanding the data. **2023**, 9, 00615-2022 ○
- 28 Real-life therapeutic effects of beclomethasone dipropionate/formoterol fumarate/glycopyrronium combined triple therapy in patients with chronic obstructive pulmonary disease. **2023**, 17, 175346662311557 ○
- 27 Idiopathic pulmonary fibrosis is more strongly associated with coronary artery disease than chronic obstructive pulmonary disease. **2023**, 211, 107195 ○
- 26 Reducing the Risk of Mortality in Chronic Obstructive Pulmonary Disease With Pharmacotherapy: A Narrative Review. **2023**, 98, 301-315 1
- 25 Budesonide/formoterol maintenance and reliever therapy versus fluticasone/salmeterol fixed-dose treatment in patients with COPD. **2023**, 78, 451-458 ○
- 24 Inhaled corticosteroids administration/withdrawal as a therapeutic continuum for patients with chronic obstructive pulmonary disease in real clinical practice. **2023**, 33, 109-118 ○
- 23 A Prediction Scoring Model for the Effect of Withdrawal or Addition of Inhaled Corticosteroids in Patients with Chronic Obstructive Pulmonary Disease. Volume 18, 113-127 ○
- 22 Clinical Impacts of Interventions for Physical Activity and Sedentary Behavior on Patients with Chronic Obstructive Pulmonary Disease. **2023**, 12, 1631 ○
- 21 Vorrangiges Therapieziel: Exazerbationen vermeiden. **2023**, 15, 46-47 ○
- 20 Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. **2023**, 59, 232-248 ○
- 19 Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. **2023**, 207, 819-837 ○
- 18 Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. **2023**, 28, 316-338 ○
- 17 Global initiative for chronic obstructive lung disease 2023 report: gold executive summary. 1-23 ○

16	Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. 2023 , 61, 2300239	1
15	Pathophysiology, Therapeutic Targets, and Future Therapeutic Alternatives in COPD: Focus on the Importance of the Cholinergic System. 2023 , 13, 476	0
14	Changes in mortality among patients with chronic obstructive pulmonary disease from the 1990s to the 2000s: a pooled analysis of two prospective cohort studies. 2023 , 13, e065896	0
13	1) COVID 19 and COPD Medical Care. 2022 , 111, 430-435	0
12	Cost Analysis of a Transition Care Bundle Compared with Usual Care for COPD Patients Being Discharged from Hospital: Evaluation of a Randomized Controlled Trial.	0
11	Impact of triple therapy on mortality in COPD. 2023 , 19, 220260	0
10	ICS/formoterol maintenance and reliever therapy: how far beyond asthma?. 2023 , 78, 430-431	0
9	The adherence to and utility of the Global Initiative for Chronic Obstructive Lung Disease guidelines for treating COPD among pulmonary specialists: A retrospective analysis.	0
8	Smoking cessation and vaccination. 2023 , 32, 220187	0
7	COPD: what GPNs need to know from the latest GOLD update. 2023 , 34, 153-157	0
6	Exacerbations Predict Severe Cardiovascular Events in Patients with COPD and Stable Cardiovascular Disease: A Nationwide, Population-Based Cohort Study. Volume 18, 419-429	0
5	Pharmacological therapy for stable chronic obstructive pulmonary disease.	0
4	COPD treatment: a conceptual review based on critical endpoints. 2023 ,	0
3	Factors Associated with the Non-Exacerbator Phenotype of Chronic Obstructive Pulmonary Disease. Volume 18, 483-492	0
2	High versus Medium Dose of Inhaled Corticosteroid in Chronic Obstructive Lung Disease: A Systematic Review and Meta-Analysis. Volume 18, 469-482	0
1	GOLD 2023: Was ist jetzt anders?. 2023 , 15, 28-31	0